Literature DB >> 26265311

Pain-related anxiety mediates the relationship between depressive symptoms and pain interference in veterans with hepatitis C.

Melissa H Adams1, Travis I Lovejoy1, Dennis C Turk2, Steven K Dobscha1, Peter Hauser3, Benjamin J Morasco4.   

Abstract

OBJECTIVE: Depression and chronic pain are common in persons chronically infected with the hepatitis C virus (HCV), although little is known about the rate of co-occurrence or mechanisms by which they are associated. We evaluated whether pain-related anxiety mediates the relationship between depressive symptoms and pain-related physical functioning in patients with HCV.
METHODS: Patients with HCV (n=175) completed self-report measures assessing demographic characteristics, pain-related function and mental health. Path analyses examined direct effects of cognitive-affective and somatic symptoms of depression on pain interference and indirect effects of these relationships via four subscales of the Pain Anxiety Symptoms Scale-20.
RESULTS: Cognitive-affective and somatic symptoms of depression were positively and significantly related to pain interference. Pain-related anxiety mediated the relationship between both cognitive-affective and somatic symptoms of depression, and this mediation was predominantly accounted for by the escape-avoidance component of pain-related anxiety.
CONCLUSIONS: Findings indicate a potential mediating role of pain-related anxiety, particularly escape-avoidance anxiety, on the relationship between depression and pain interference in patients with HCV. These findings suggest that escape-avoidance anxiety may be a particularly germane target for treatment in patients with HCV and chronic pain, particularly when depression, with characteristic features of withdrawal and inhibition, is a comorbid condition. Published by Elsevier Inc.

Entities:  

Keywords:  Chronic pain; Comorbidity; Depression; Hepatitis C virus; Pain-related anxiety

Mesh:

Year:  2015        PMID: 26265311      PMCID: PMC4630124          DOI: 10.1016/j.genhosppsych.2015.07.003

Source DB:  PubMed          Journal:  Gen Hosp Psychiatry        ISSN: 0163-8343            Impact factor:   3.238


  47 in total

Review 1.  Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review.

Authors:  E Dieperink; M Willenbring; S B Ho
Journal:  Am J Psychiatry       Date:  2000-06       Impact factor: 18.112

2.  Comparing the effectiveness of mindfulness-based stress reduction and multidisciplinary intervention programs for chronic pain: a randomized comparative trial.

Authors:  Samuel Yeung-Shan Wong; Frank Wan-Kin Chan; Rebecca Lai-Ping Wong; Ming-Chi Chu; Yu-Yuk Kitty Lam; Stewart W Mercer; S Helen Ma
Journal:  Clin J Pain       Date:  2011-10       Impact factor: 3.442

Review 3.  Neuroimmune mechanisms of cytokine-induced depression: current theories and novel treatment strategies.

Authors:  Jennifer M Loftis; Marilyn Huckans; Benjamin J Morasco
Journal:  Neurobiol Dis       Date:  2009-11-26       Impact factor: 5.996

4.  Fear of movement/(re)injury in chronic low back pain and its relation to behavioral performance.

Authors:  Johan W S Vlaeyen; Ank M J Kole-Snijders; Ruben G B Boeren; H van Eek
Journal:  Pain       Date:  1995-09       Impact factor: 6.961

5.  Illness-related stigma, mood and adjustment to illness in persons with hepatitis C.

Authors:  Jeannette Golden; Ronán Michael Conroy; Ann Marie O'Dwyer; Daniel Golden; Jean-Benoit Hardouin
Journal:  Soc Sci Med       Date:  2006-09-28       Impact factor: 4.634

6.  A comprehensive yoga programs improves pain, anxiety and depression in chronic low back pain patients more than exercise: an RCT.

Authors:  P Tekur; R Nagarathna; S Chametcha; Alex Hankey; H R Nagendra
Journal:  Complement Ther Med       Date:  2012-01-28       Impact factor: 2.446

7.  A brief cognitive-behavioral approach to reducing anxiety sensitivity decreases pain-related anxiety.

Authors:  Margo C Watt; Sherry H Stewart; Marie-Josée Lefaivre; Lindsay S Uman
Journal:  Cogn Behav Ther       Date:  2006

8.  A randomized, controlled trial of acceptance and commitment therapy and cognitive-behavioral therapy for chronic pain.

Authors:  Julie Loebach Wetherell; Niloofar Afari; Thomas Rutledge; John T Sorrell; Jill A Stoddard; Andrew J Petkus; Brittany C Solomon; David H Lehman; Lin Liu; Ariel J Lang; J Hampton Atkinson
Journal:  Pain       Date:  2011-06-17       Impact factor: 6.961

9.  Depression, anemia and health-related quality of life in chronic hepatitis C.

Authors:  Amy A Dan; Lisa M Martin; Cathy Crone; Janus P Ong; Denise W Farmer; Thomas Wise; Sean C Robbins; Zobair M Younossi
Journal:  J Hepatol       Date:  2005-12-27       Impact factor: 25.083

10.  Depressive symptoms in patients with chronic hepatitis C are correlated with elevated plasma levels of interleukin-1beta and tumor necrosis factor-alpha.

Authors:  Jennifer M Loftis; Marilyn Huckans; Samantha Ruimy; David J Hinrichs; Peter Hauser
Journal:  Neurosci Lett       Date:  2007-11-06       Impact factor: 3.046

View more
  4 in total

1.  Characterising the association between positive hepatitis C virus antibody and pain among people who inject drugs.

Authors:  Michelle Ng; Kanna Hayashi; Pauline Voon; Hennady P Shulha; Kora DeBeck; M-J Milloy; Lianping Ti
Journal:  Drug Alcohol Rev       Date:  2019-08-16

2.  Development and Preliminary Evaluation of an Integrated Cognitive-Behavior Treatment for Chronic Pain and Substance Use Disorder in Patients with the Hepatitis C Virus.

Authors:  Benjamin J Morasco; David W Greaves; Travis I Lovejoy; Dennis C Turk; Steven K Dobscha; Peter Hauser
Journal:  Pain Med       Date:  2016-06-27       Impact factor: 3.750

3.  Depression explains the association between pain intensity and pain interference among adults with neurofibromatosis.

Authors:  James D Doorley; Jonathan Greenberg; Jafar Bakhshaie; Nathan S Fishbein; Ana-Maria Vranceanu
Journal:  J Neurooncol       Date:  2021-08-19       Impact factor: 4.506

4.  A Survey on the Prevalence of Depression in Blood Donors with Hepatitis C in Shiraz.

Authors:  Leila Kasraian; Neda Negarestani; Mohammad Hossein Karimi; Sahar Dehbidi
Journal:  Hepat Mon       Date:  2016-11-06       Impact factor: 0.660

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.